Julphar has agreed to a binding offer by Al-Bat’ha Healthcare Group for the acquisition of select retail and distribution assets, aiming to enhance its market presence and operational efficiency in the UAE and Oman.

Information on the Target

Gulf Pharmaceutical Industries (Julphar), a leading pharmaceutical company in the Middle East and North Africa, has shown consistent growth in sales and stable profits. As of September 2025, Julphar reported a net revenue of AED 249.7 million for Q3, representing a 5.0% increase compared to the previous year. Cumulatively, overall revenues reached AED 796.1 million for the first nine months of 2025, reflecting a year-on-year growth of 5.8%. The company has enhanced its operational profitability, with EBITDA rising from AED 80.5 million to AED 108.7 million, demonstrating its focus on cost efficiency and operational discipline.

Julphar's strong financial performance has been bolstered by strategic initiatives, including the launch of eleven new products and the achievement of 23 regulatory approvals. The overall gross profit also increased to AED 351.1 million, maintaining a remarkable margin of 44.0%. Additionally, a substantial turnaround in net income was observed, improving from a loss of AED 9.9 million to a profit of AED 36.7 million compared to the prior year. This growth comes at a pivotal time as Julphar has been expanding its market presence.

Industry Overview

The pharmaceutical industry in the UAE is witnessing significant growth due to an increasing population, rising demand for healthcare services, and government initiatives aimed at improving healthcare accessibility. The sector is rapidly evolving with local and international com